Karl is co-founder of Aglaia BioMedical Ventures. He holds an MBA from the University of Georgia (USA), following his studies at The Netherlands School of Business, Nijenrode. Before starting up Aglaia, he was involved in the founding, restructuring and funding of multiple technology-driven companies. In 1995, he founded Entity Holding B.V., a venture company focusing on early-stage companies. Karl serves at the board of a number of life sciences companies.
Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer
Inthera Bioscience raises CHF 10.5 million in Series A financing round